Profile data is unavailable for this security.
About the company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
- Revenue in USD (TTM)2.00m
- Net income in USD-29.25m
- Incorporated2006
- Employees10.00
- LocationSagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
- Phone+1 (650) 561-8600
- Fax+1 (302) 730-1370
- Websitehttps://sagimet.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.76m | 105.31m | 20.00 | -- | 1.71 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 106.05m | 31.00 | -- | 1.08 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 108.82m | 10.00 | -- | 0.5885 | -- | 54.41 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Verastem Inc | 10.00m | -89.49m | 109.06m | 73.00 | -- | 3.86 | -- | 10.91 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 109.13m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 110.20m | 54.00 | -- | 1.68 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 110.30m | 9.00 | -- | 19.92 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 110.52m | -- | 6.41 | 0.2236 | 57.16 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 110.74m | 23.00 | -- | -- | -- | 1,419.79 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 111.02m | 4.00 | -- | 5.09 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 112.72m | 74.00 | -- | 0.7046 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 113.04m | 25.00 | -- | 3.65 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 113.92m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 114.51m | 31.00 | -- | 2.14 | -- | 172.20 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 115.08m | 11.00 | -- | 2.76 | -- | 1,353.82 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 115.30m | 65.00 | -- | 3.32 | -- | 5.37 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Data as of Sep 19 2024. Currency figures normalised to Sagimet Biosciences Inc's reporting currency: US Dollar USD
35.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 30 Jun 2024 | 2.37m | 7.71% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 1.38m | 4.51% |
| Alyeska Investment Group LPas of 30 Jun 2024 | 1.28m | 4.17% |
| Citadel Advisors LLCas of 30 Jun 2024 | 1.19m | 3.89% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.07m | 3.48% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 787.81k | 2.57% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 733.02k | 2.39% |
| HHLR Advisors Ltd.as of 30 Jun 2024 | 724.80k | 2.36% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 724.77k | 2.36% |
| PFM Health Sciences LPas of 30 Jun 2024 | 649.01k | 2.12% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
